Cargando…

Defining the heterogeneity of unbalanced structural variation underlying breast cancer susceptibility by nanopore genome sequencing

Germline structural variants (SVs) are challenging to resolve by conventional genetic testing assays. Long-read sequencing has improved the global characterization of SVs, but its sensitivity at cancer susceptibility loci has not been reported. Nanopore long-read genome sequencing was performed for...

Descripción completa

Detalles Bibliográficos
Autores principales: Dixon, Katherine, Shen, Yaoqing, O’Neill, Kieran, Mungall, Karen L., Chan, Simon, Bilobram, Steve, Zhang, Wei, Bezeau, Marjorie, Sharma, Alshanee, Fok, Alexandra, Mungall, Andrew J., Moore, Richard, Bosdet, Ian, Thibodeau, My Linh, Sun, Sophie, Yip, Stephen, Schrader, Kasmintan A., Jones, Steven J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172360/
https://www.ncbi.nlm.nih.gov/pubmed/36797466
http://dx.doi.org/10.1038/s41431-023-01284-1
Descripción
Sumario:Germline structural variants (SVs) are challenging to resolve by conventional genetic testing assays. Long-read sequencing has improved the global characterization of SVs, but its sensitivity at cancer susceptibility loci has not been reported. Nanopore long-read genome sequencing was performed for nineteen individuals with pathogenic copy number alterations in BRCA1, BRCA2, CHEK2 and PALB2 identified by prior clinical testing. Fourteen variants, which spanned single exons to whole genes and included a tandem duplication, were accurately represented. Defining the precise breakpoints of SVs in BRCA1 and CHEK2 revealed unforeseen allelic heterogeneity and informed the mechanisms underlying the formation of recurrent deletions. Integrating read-based and statistical phasing further helped define extended haplotypes associated with founder alleles. Long-read sequencing is a sensitive method for characterizing private, recurrent and founder SVs underlying breast cancer susceptibility. Our findings demonstrate the potential for nanopore sequencing as a powerful genetic testing assay in the hereditary cancer setting.